SOBI

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News

Sobi plans filings for gout drug after phase 3 readout

SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.

News

Sanofi gets FDA nod for long-acting haemophilia A drug

Once-weekly Altuviiio could be potential $2 billion-plus blockbuster, according to analysts.

News

Priority review sets up Feb verdict on Sanofi, Sobi haemophi...

The FDA will carry out a speedy review of Sanofi and Sobi's once-weekly haemophilia A treatment efanesoctocog alfa (Bivv001), with a decision now

News

Red blood cells moving in blood vessels with depth of field.

Sanofi trumpets data with haemophilia treatment duo at ISTH

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at th

News

Sobi bolsters blood division via $435m ADC licensing deal

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics' lymphoma therapy Zynlonta – approved in the US last year – in Europe and other inte

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Sobi plans filings for gout drug after phase 3 readout

Sanofi gets FDA nod for long-acting haemophilia A drug

Priority review sets up Feb verdict on Sanofi, Sobi haemophi...

Sanofi trumpets data with haemophilia treatment duo at ISTH

Sobi bolsters blood division via $435m ADC licensing deal

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

SOBI

Editor's Picks